A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Public ClinicalTrials.gov record NCT06006585. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety, Tolerability, and Pharmacokinetics of Intravitreal Single Rising Doses and Multiple Doses of BI 771716 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old. The purpose of this study is to find out how well different doses of a medicine called BI 771716 are tolerated. This study has 2 parts. Part 1 of the study takes about 3 months. In this part, participants receive 1 injection of BI 771716 directly into one of the eyes affected by geographic atrophy. Part 2 of the study takes about 4 months. In this part, participants receive 2 injections of BI 771716 directly into the eye. There are 4 weeks between the first and the second injection. In this study, BI 771716 is given to humans for the first time. The doctors compare how well participants tolerate the different doses of BI 771716. The doctors also regularly check the general health of the participants.
Study identification
- NCT ID
- NCT06006585
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 20 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2023
- Primary completion
- May 23, 2024
- Completion
- May 23, 2024
- Last update posted
- Feb 17, 2025
2023 – 2024
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bay Area Retina Associates - Walnut Creek | Walnut Creek | California | 94598 | — |
| Florida Retina Institute | Jacksonville | Florida | 32204 | — |
| Florida Eye Associates | Melbourne | Florida | 32901 | — |
| Verum Research, LLC | Eugene | Oregon | 97401 | — |
| Erie Retina Research, LLC | Erie | Pennsylvania | 16507 | — |
| Tennessee Retina | Nashville | Tennessee | 37215 | — |
| Austin Clinical Research, LLC | Austin | Texas | 78750 | — |
| Retina Consultants of Houston, PA-Houston-62050 | Houston | Texas | 77030 | — |
| Retina Consultants of Texas-The Woodlands-67575 | The Woodlands | Texas | 77384 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Geographic Atrophy trials
Other public records listing Geographic Atrophy. Sorted by last update posted; newest first. Not a recommendation.
- NCT04339764: Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration Recruiting
- NCT07606365: A Study in Adults With Geographic Atrophy Not yet recruiting
- NCT07594236: Phase 1 Study of C.001 in Retinal Degeneration Recruiting
- NCT06722157: A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy Active, not recruiting
- NCT06961370: A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Active, not recruiting
- NCT01866371: High Resolution Retinal Imaging Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06006585, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 17, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06006585 live on ClinicalTrials.gov.